Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Steve Yang: AstraZeneca in China Wants to Transform Pharma R&D Models

publication date: Feb 3, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Steve Yang, AstraZeneca’s high profile VP and Head of R&D for Asian and Emerging Markets, is setting an ambitious goal for the company’s China R&D operation: “We will try to innovate and transform how we do R&D,” said Yang in a McKinsey Quarterly interview. Because innovative pharma development is still new in China, “we are starting with a clean slate,” he added. “But that could be an opportunity,” given that established ways of doing drug R&D are not institutionalized, leaving China free to map its own path. More details....

Stock Symbol: (NYSE: AZN)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners